Matinas BioPharma
MTNB
51 hedge funds and large institutions have $9.31M invested in Matinas BioPharma in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 14 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
2% more funds holding
Funds holding: 50 → 51 (+1)
0.01% less ownership
Funds ownership: 0.25% → 0.24% (-0.01%)
26% less capital invested
Capital invested by funds: $12.6M → $9.31M (-$3.29M)
57% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$261K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$71.9K |
| 3 |
VF
Virtu Financial
New York
|
+$42.1K |
| 4 |
BlackRock
New York
|
+$18.5K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$9.35K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NRS
Neville Rodie & Shaw
New York
|
-$278K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$166K |
| 3 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
-$153K |
| 4 |
Millennium Management
New York
|
-$90.5K |
| 5 |
Jane Street
New York
|
-$27.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IA
51
IFP Advisors
Tampa,
Florida
| $231 | – | – | – |
|
|
52
Jane Street
New York
| – | -$27.2K | -1,159 | Closed |
|
53
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$6.92K | -295 | Closed |
|
|
FAIM
54
Financial Advocates Investment Management
Olympia,
Washington
| – | -$4.7K | -200 | Closed |
|
55
BNP Paribas Financial Markets
Paris,
France
| – | -$37 | -2 | Closed |
|
56
Bank of America
Charlotte,
North Carolina
| – | -$3 | – | – |
|
MTNB Hedge Fund Activity: Q2 2023 in Review
51 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2023, worth a combined $9.31M — down 26% from $12.6M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new MTNB positions and 4 closed out — a net gain of 1 holder — while 6 added to existing stakes and 14 trimmed.
The largest buyer was Wells Fargo, adding an estimated $261K. The largest seller was Neville Rodie & Shaw, cutting an estimated $278K.
- 51 institutional investors held Matinas BioPharma (MTNB) as of Q2 2023, up from 50 in Q1 2023.
- Funds reported $9.31M of Matinas BioPharma stock for Q2 2023, down 26% quarter-over-quarter.
- 5 funds opened new Matinas BioPharma positions in Q2 2023 and 4 closed out, a net change of +1 holder.
- The largest Matinas BioPharma buyer in Q2 2023 was Wells Fargo, an estimated $261K added.
- The largest Matinas BioPharma seller in Q2 2023 was Neville Rodie & Shaw, an estimated $278K sold.
Based on aggregated 13F filings for Q2 2023.